There
is currently great excitement among clinicians and scientists in the field of
personalized treatment of cancer. Today’s advances in the biology of cancer and
development of new tools for genome analysis have provided for a fresh
perspective in what is commonly known today as personalized medicine. This type
of medicine is centered on the tumor. The concept is not new and previous
attempts to customize treatment have been carried out by the patient himself.
Despite its limitations, decades ago body surface area based dosing was already
a first step in this promising treatment type. Today, application of new
pharmacokinetics (PK) and pharmacogenetics-driven concepts still provide some
of the most promising tools for improving treatment management and clinical
outcomes in patients with cancer.
Transgenomic
is a global biotechnology company pushing the envelope on personalized medicine
in cardiology, oncology, and inherited diseases through its proprietary
molecular technologies and research services. The company is the global leader
in cardiac genetic testing with several products, including its flagship C-GAAP
test. The test is designed to detect gene mutations which indicate cardiac
disorders, or which can lead to adverse problems down the road. Transgenomic
has three divisions. They are Transgenomic Clinical Laboratories, which
specializes in molecular diagnostics for cardiology, oncology, neurology, and
mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract
research laboratory that specializes in supporting all phases of pre-clinical
and clinical trials for oncology drugs in development; and Transgenomic
Diagnostic Tools, a producer of equipment, reagents, and other consumables that
aid clinical and research applications in molecular testing and cytogenetics.
Transgenomic sees great opportunity for further growth in all three businesses
by using their synergistic capabilities, technologies, and expertise.
TBIO’s
management team is built for success. Sandra J. Gunselman Ph. D. and Vice
President of Clinical Operations achieved a B.S. in Biology from the David
Lipscomb University and a Ph.D. in Cellular & Molecular Biology from
Colorado State University. Dr. Gunselman has two decades of molecular biology
lab experience. Dr. Gunselman specializes in DNA damage and repair.
For
more information on the company, visit www.transgenomic.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html